Open Access

Macamide B suppresses lung cancer progression potentially via the ATM signaling pathway

  • Authors:
    • Haiyan Tao
    • Hubo Shi
    • Min Wang
    • Yihui Xu
  • View Affiliations

  • Published online on: February 6, 2023     https://doi.org/10.3892/ol.2023.13701
  • Article Number: 115
  • Copyright: © Tao et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Macamides are a class of bioactive natural products obtained from Lepidium meyenii (maca), which have been reported to exert inhibitory activity in cancer. However, their role in lung cancer is currently unknown. In the present study, macamide B was shown to inhibit the proliferation and invasion of lung cancer cells, as determined by Cell Counting Kit‑8 and Transwell assays, respectively. By contrast, macamide B induced cell apoptosis, as determined by Annexin V‑FITC assay. Moreover, combined treatment with macamide B and olaparib, an inhibitor of poly (ADP‑ribose) polymerase, further suppressed the proliferation of lung cancer cells. At the molecular level, the expression of ataxia‑telangiectasia mutated (ATM), RAD51, p53 and cleaved caspase‑3 were significantly increased by macamide B, as determined by western blotting, whereas the expression levels of Bcl‑2 were decreased. By contrast, when ATM expression was knocked down by small interfering RNA technology in A549 cells treated with macamide B, the expression levels of ATM, RAD51, p53 and cleaved caspase‑3 were reduced, whereas those of Bcl‑2 were increased. Consistently, cell proliferation and invasive ability were partially rescued by ATM knockdown. In conclusion, macamide B inhibits lung cancer progression by inhibiting cell proliferation and invasion, and inducing apoptosis. Furthermore, macamide B may participate in regulating the ATM signaling pathway. The present study provides a potential new natural drug for treating patients with lung cancer.
View Figures
View References

Related Articles

Journal Cover

March-2023
Volume 25 Issue 3

Print ISSN: 1792-1074
Online ISSN:1792-1082

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Tao H, Shi H, Wang M and Xu Y: Macamide B suppresses lung cancer progression potentially via the ATM signaling pathway. Oncol Lett 25: 115, 2023.
APA
Tao, H., Shi, H., Wang, M., & Xu, Y. (2023). Macamide B suppresses lung cancer progression potentially via the ATM signaling pathway. Oncology Letters, 25, 115. https://doi.org/10.3892/ol.2023.13701
MLA
Tao, H., Shi, H., Wang, M., Xu, Y."Macamide B suppresses lung cancer progression potentially via the ATM signaling pathway". Oncology Letters 25.3 (2023): 115.
Chicago
Tao, H., Shi, H., Wang, M., Xu, Y."Macamide B suppresses lung cancer progression potentially via the ATM signaling pathway". Oncology Letters 25, no. 3 (2023): 115. https://doi.org/10.3892/ol.2023.13701